Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Meta-analysis of tumor immunogenicity using large public tumor sequence data sets

FY 2013-14

Summary
Cells continuously break up their intracellular proteins and present these small fragments, called antigens, on their cell surface for surveying by T cells. As part of adaptive immunity, a repertoire of T cells, each recognizing a specific presented antigen, survey these antigens and determine whether its source is foreign, such as a viral infection or a cancer causing mutation, or native to the cell. If a T cell determines the antigen is of foreign origin, it will kill the cell carrying that antigen, and create more of itself to increase the likelihood of detecting that specific antigen elsewhere in the body. Vaccines are comprised of antigens, and upon vaccination, these antigens are presented to the T cells, causing them to become activated and multiply. This in turn increases the overall sensitivity to that antigen in the body, enhancing the ability of the T cells to identify and eliminate other cells presenting these same antigens. Our goal is to predict tumor antigens from tumors using computational methods. The DNA of tumors contain mutations which may be manifested in various antigens. If we are able to predict these antigens for each patient, they can be used in developing personalized vaccines for that specific cancer, helping the body in the detection and destruction of the tumor cells. The Cancer Genome Atlas (TCGA) is an initiative of the National Institutes of Health, and has created a comprehensive catalogue of tumor mutations from thousands of patients from 20 different cancer types. Along with these tumor mutations, it catalogues both DNA sequences and clinical data for each individual patient. We will use these publically available data to predict, computationally, which mutations will give rise to antigens that are easily detected by T cells (antigenic). The mutations we will look at include those validated in the TCGA data, as well as non-curated gene fusions. Gene fusions occur when two genes become spliced together, and are very common in cancer. Due to their dramatic departure from a “normal” DNA sequence, they require specialized algorithms for detection from DNA sequence data which take into account their unique fusions. Initial analysis using the catalogued mutations has revealed that tumors with high numbers of antigenic mutations had more T cells than those patients with low numbers of antigenic mutations, which makes sense under the assumption that these T cells are recognizing these antigens. Curiously, there exist specific cases where a tumor had no antigenic mutations, yet had high numbers of T cells. We currently do not know what is causing these high numbers of T cells and we hypothesize that these are cases where the gene fusion information may be very informative. We also wish to create a way of scoring each tumor on its antigenic potential, based on the number of antigenic mutations, and various scores from computational prediction algorithms. These algorithms will predict how well each step in the processing of an antigen will succeed, from expression of the gene from the DNA sequence to the antigen being presented on the cell surface, and all steps in between. This research has direct clinical implications. Being able to predict whether a specific tumor has antigenic mutations will allow for more informed treatment decisions. If a tumor is found with no antigenic mutations, there is nothing for the T cells to detect, and thus traditional treatments are more likely to be effective in these cases. Alternatively, patients with tumors having lots of antigenic mutations can benefit from the development of personalized vaccines, and may also benefit from recently developed drugs which prevent T cell inhibition. Both of these allow the body’s own immune system to destroy the tumor itself.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311954
Name
Brown Scott D
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Meta-analysis of tumor immunogenicity using large public tumor sequence data sets
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antigens; Bioinformatics; Cancer Genomics; Computational Biology; Epitopes; Genomics; Immunology
Abstract
Cells continuously break up their intracellular proteins and present these small fragments, called antigens, on their cell surface for surveying by T cells. As part of adaptive immunity, a repertoire of T cells, each recognizing a specific presented antigen, survey these antigens and determine whether its source is foreign, such as a viral infection or a cancer causing mutation, or native to the cell. If a T cell determines the antigen is of foreign origin, it will kill the cell carrying that antigen, and create more of itself to increase the likelihood of detecting that specific antigen elsewhere in the body. Vaccines are comprised of antigens, and upon vaccination, these antigens are presented to the T cells, causing them to become activated and multiply. This in turn increases the overall sensitivity to that antigen in the body, enhancing the ability of the T cells to identify and eliminate other cells presenting these same antigens. Our goal is to predict tumor antigens from tumors using computational methods. The DNA of tumors contain mutations which may be manifested in various antigens. If we are able to predict these antigens for each patient, they can be used in developing personalized vaccines for that specific cancer, helping the body in the detection and destruction of the tumor cells. The Cancer Genome Atlas (TCGA) is an initiative of the National Institutes of Health, and has created a comprehensive catalogue of tumor mutations from thousands of patients from 20 different cancer types. Along with these tumor mutations, it catalogues both DNA sequences and clinical data for each individual patient. We will use these publically available data to predict, computationally, which mutations will give rise to antigens that are easily detected by T cells (antigenic). The mutations we will look at include those validated in the TCGA data, as well as non-curated gene fusions. Gene fusions occur when two genes become spliced together, and are very common in cancer. Due to their dramatic departure from a “normal” DNA sequence, they require specialized algorithms for detection from DNA sequence data which take into account their unique fusions. Initial analysis using the catalogued mutations has revealed that tumors with high numbers of antigenic mutations had more T cells than those patients with low numbers of antigenic mutations, which makes sense under the assumption that these T cells are recognizing these antigens. Curiously, there exist specific cases where a tumor had no antigenic mutations, yet had high numbers of T cells. We currently do not know what is causing these high numbers of T cells and we hypothesize that these are cases where the gene fusion information may be very informative. We also wish to create a way of scoring each tumor on its antigenic potential, based on the number of antigenic mutations, and various scores from computational prediction algorithms. These algorithms will predict how well each step in the processing of an antigen will succeed, from expression of the gene from the DNA sequence to the antigen being presented on the cell surface, and all steps in between. This research has direct clinical implications. Being able to predict whether a specific tumor has antigenic mutations will allow for more informed treatment decisions. If a tumor is found with no antigenic mutations, there is nothing for the T cells to detect, and thus traditional treatments are more likely to be effective in these cases. Alternatively, patients with tumors having lots of antigenic mutations can benefit from the development of personalized vaccines, and may also benefit from recently developed drugs which prevent T cell inhibition. Both of these allow the body’s own immune system to destroy the tumor itself.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brown, Scott D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~